Recent studies have demonstrated that alternative promoter is an important regulator in tumor-related gene (e.g. SEPT9 and CTNNB1) and tumor signaling pathways (e.g. NF-κB and STING), indicating that paQTLs might impact patient prognosis by regulating promoter activity of cancer-related genes or cancer-related pathways. This evidence concerns the gene NFKB1 and neoplasm.